Please provide your email address to receive an email when new articles are posted on . Time in range, time below range and glucose management indicator are three CGM metrics with limitations.

The SURPASS-2 trial compared three doses of tirzepatide (5 mg, 10 mg, 15 mg) with semaglutide 1 mg, in adults with type 2 diabetes who were already taking metformin. The primary aim was ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Recent advances in diabetes detection may help to identify risk earlier. In this article, MNT discusses recent studies that ...

Accurate glycemic-monitoring and control of the patients with hyperglycemia/diabetes are essential for better patient care management. Hemoglobin A1c (HbA1c) measurements correlate with the average ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor ...

A new saliva test and earlier use of the HbA 1c blood test could pick up type 2 diabetes in high-risk patients earlier than methods in current use, show data from 2 studies. Both tests could both ...

The approval of medicines called “glucagon-like peptide (GLP-1) agonists” has led to major changes in how type 2 diabetes is managed. These medicines work in a different way than other medicines used ...